{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:21:59Z","timestamp":1791141719908,"version":"4.1.0"},"reference-count":377,"publisher":"The Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,10,1]]},"DOI":"10.1210\/er.2002-0015","type":"journal-article","created":{"date-parts":[[2003,10,22]],"date-time":"2003-10-22T01:28:48Z","timestamp":1066786128000},"page":"633-667","source":"Crossref","is-referenced-by-count":207,"title":["Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome"],"prefix":"10.1210","volume":"24","author":[{"given":"Vincenzo","family":"De Leo","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Obstetrics, and Reproductive Medicine, Institute of Obstetrics and Gynecology, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"la Marca","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Obstetrics, and Reproductive Medicine, Institute of Obstetrics and Gynecology, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Petraglia","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Obstetrics, and Reproductive Medicine, Institute of Obstetrics and Gynecology, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2016,11,7]]},"reference":[{"key":"2019041121320420100_R1","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2337\/diab.38.9.1165","article-title":"Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome.","volume":"38","author":"Dunaif","year":"1989","journal-title":"Diabetes"},{"key":"2019041121320420100_R2","first-page":"774","article-title":"Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.","volume":"18","author":"Dunaif","year":"1997","journal-title":"Endocr Rev"},{"key":"2019041121320420100_R3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0889-8529(05)70079-7","article-title":"Cardiovascular consequences of polycystic ovary syndrome.","volume":"28","author":"Amowitz","year":"1999","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2019041121320420100_R4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.1999.tb07782.x","article-title":"The metabolic syndrome X.","volume":"892","author":"Hansen","year":"1999","journal-title":"Ann NY Acad Sci"},{"key":"2019041121320420100_R5","first-page":"377","author":"Zawedzki","year":"1992"},{"key":"2019041121320420100_R6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0889-8545(05)70184-4","article-title":"Neuromodulation in polycystic ovary syndrome.","volume":"28","author":"Kalro","year":"2001","journal-title":"Obstet Gynecol Clin North Am"},{"key":"2019041121320420100_R7","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1172\/JCI108400","article-title":"Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.","volume":"57","author":"Rebar","year":"1976","journal-title":"J Clin Invest"},{"key":"2019041121320420100_R8","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0015-0282(16)41228-8","article-title":"Gonadotropin levels and secretory patterns in patients with typical and atypical polycystic ovarian disease.","volume":"26","author":"Berger","year":"1975","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1056\/NEJM198903023200904","article-title":"Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome.","volume":"320","author":"Barnes","year":"1989","journal-title":"N Engl J Med"},{"key":"2019041121320420100_R10","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1210\/er.16.3.322","article-title":"Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion.","volume":"16","author":"Ehrmann","year":"1995","journal-title":"Endocr Rev"},{"key":"2019041121320420100_R11","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJM198311173092002","article-title":"A chronobiologic abnormality in luteinizing hormone secretion in teenage girls with the polycystic-ovary syndrome.","volume":"309","author":"Zumoff","year":"1983","journal-title":"N Engl J Med"},{"key":"2019041121320420100_R12","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1210\/jcem-68-6-1111","article-title":"Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.","volume":"68","author":"Ziegler","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1210\/jcem-49-3-335","article-title":"An attenuated form of congenital virilizing adrenal hyperplasia.","volume":"49","author":"Rosenwaks","year":"1979","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1210\/jcem-69-1-151","article-title":"The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects.","volume":"69","author":"Spinder","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R15","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1210\/jcem-64-4-675","article-title":"Differential control of luteinizing hormone and follicle-stimulating hormone secretion by luteinizing hormone-releasing hormone pulse frequency in man.","volume":"64","author":"Gross","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R16","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1210\/jcem-64-6-1179","article-title":"Effects of increasing the frequency of low doses of gonadotropin-releasing hormone (GnRH) on gonadotropin secretion in GnRH-deficient men.","volume":"64","author":"Spratt","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0889-8529(05)70071-2","article-title":"Neuroendocrine aspects of polycystic ovary syndrome.","volume":"28","author":"Marshall","year":"1999","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2019041121320420100_R18","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/BF03350785","article-title":"Insights into hypothalamic-pituitary dysfunction in polycystic ovary syndrome.","volume":"21","author":"Hall","year":"1998","journal-title":"J Endocrinol Invest"},{"key":"2019041121320420100_R19","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/0002-9378(92)91779-A","article-title":"Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?","volume":"167","author":"Carmina","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"2019041121320420100_R20","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1210\/jcem-57-2-393","article-title":"Evidence for the importance of peripheral tissue events in the development of hirsutism in polycystic ovary syndrome.","volume":"57","author":"Lobo","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/jcem-33-2-199","article-title":"Combined ovarian and adrenal vein catheterization to determine the site(s) of androgen overproduction in hirsute women.","volume":"33","author":"Kirschner","year":"1971","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R22","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM197603182941204","article-title":"Idiopathic hirsutism\u2014 an ovarian abnormality.","volume":"294","author":"Kirschner","year":"1976","journal-title":"N Engl J Med"},{"key":"2019041121320420100_R23","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1210\/jcem-34-1-92","article-title":"Adrenal and ovarian contributions to the elevated free plasma androgen levels in hirsute women.","volume":"34","author":"Rosenfield","year":"1972","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R24","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0002-9378(16)33087-3","article-title":"Ovarian hyperandrogenism with normal and abnormal histologic findings of the ovaries.","volume":"134","author":"Kim","year":"1979","journal-title":"Am J Obstet Gynecol"},{"key":"2019041121320420100_R25","first-page":"1686","article-title":"Studies of the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism.","volume":"79","author":"Rosenfield","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R26","first-page":"4103","article-title":"Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.","volume":"81","author":"Ibanez","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2265.1999.00770.x","article-title":"Ovarian responses to hCG stimulation: insulin resistance\/hyperinsulinaemia vs. insulin deficiency.","volume":"51","author":"Witchel","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041121320420100_R28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/humrep\/15.1.21","article-title":"Metformin treatment reduces ovarian cytochrome P-450c17\u03b1 response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome.","volume":"15","author":"la Marca","year":"2000","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R29","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1210\/mend.13.6.0311","article-title":"Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries.","volume":"13","author":"Nelson","year":"1999","journal-title":"Mol Endocrinol"},{"key":"2019041121320420100_R30","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1210\/jcem.86.12.8088","article-title":"The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome.","volume":"86","author":"Nelson","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R31","first-page":"2304","article-title":"Differential activity of the cytochrome P450 17\u03b1-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells.","volume":"85","author":"Wickenheisser","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R32","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0015-0282(16)35047-6","article-title":"Clinical and biochemical features of polycystic ovarian disease.","volume":"14","author":"Goldzieher","year":"1963","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0015-0282(98)00455-5","article-title":"Do hyperandrogenic women with normal menses have polycystic ovary syndrome?","volume":"71","author":"Carmina","year":"1999","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/humrep\/15.1.24","article-title":"Women with polycystic ovary syndrome gain regular menstrual cycles when ageing.","volume":"15","author":"Elting","year":"2000","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R35","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199509283331307","article-title":"Polycystic ovary syndrome.","volume":"333","author":"Franks","year":"1989","journal-title":"N Engl J Med"},{"key":"2019041121320420100_R36","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1136\/bmj.297.6655.1027","article-title":"Recurrent early miscarriage and polycystic ovaries.","volume":"297","author":"Sagle","year":"1988","journal-title":"Br Med J"},{"key":"2019041121320420100_R37","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/oxfordjournals.humrep.a138703","article-title":"An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases.","volume":"9","author":"Clifford","year":"1994","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R38","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1471-0528.1993.tb12978.x","article-title":"Polycystic ovaries and levels of gonadotrophins and androgen in recurrent miscarriage: prospective study in 50 women.","volume":"100","author":"Tulppala","year":"1993","journal-title":"Br J Obstet Gynaecol"},{"key":"2019041121320420100_R39","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1093\/humrep\/16.12.2606","article-title":"Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment.","volume":"16","author":"Wang","year":"2001","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R40","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1471-0528.2000.tb11670.x","article-title":"Endocrinological and endometrial factors in recurrent miscarriage.","volume":"107","author":"Li","year":"2000","journal-title":"Br J Obstet Gynaecol"},{"key":"2019041121320420100_R41","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/humrep\/15.3.612","article-title":"Polycystic ovaries and recurrent miscarriage\u2013a reappraisal.","volume":"15","author":"Rai","year":"2000","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R42","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0026-0495(99)90250-0","article-title":"Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome.","volume":"48","author":"Glueck","year":"1999","journal-title":"Metabolism"},{"key":"2019041121320420100_R43","first-page":"514","article-title":"Oligomenorrhoea, polycystic ovary syndrome and recurring miscarriage.","volume":"58","author":"Kumar","year":"1997","journal-title":"Br J Hosp Med"},{"key":"2019041121320420100_R44","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1479-828X.1997.tb02447.x","article-title":"Recurrent miscarriage: screening for polycystic ovaries and subsequent pregnancy outcome.","volume":"37","author":"Liddell","year":"1997","journal-title":"Aust NZ J Obstet Gynaecol"},{"key":"2019041121320420100_R45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1471-0528.1994.tb13131.x","article-title":"Polycystic ovaries and levels of gonadotrophins and androgens in recurrent miscarriage: prospective study in 50 women.","volume":"101","author":"Leigh","year":"1994","journal-title":"Br J Obstet Gynaecol"},{"key":"2019041121320420100_R46","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/oxfordjournals.humrep.a138149","article-title":"Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriage.","volume":"8","author":"Watson","year":"1993","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R47","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/0140-6736(91)90335-M","article-title":"Raised luteinising hormone and spontaneous miscarriage.","volume":"337","author":"Turner","year":"1991","journal-title":"Lancet"},{"key":"2019041121320420100_R48","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/0140-6736(90)92215-4","article-title":"Recurrent miscarriage. II. Clinical associations, causes, and management.","volume":"336","author":"Stirrat","year":"1990","journal-title":"Lancet"},{"key":"2019041121320420100_R49","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0015-0282(16)60457-0","article-title":"Etiology of miscarriage in polycystic ovary syndrome.","volume":"51","author":"Homburg","year":"1989","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R50","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/0140-6736(90)92765-A","article-title":"Hypersecretion of luteinizing hormone, infertility, and miscarriage.","volume":"336","author":"Regan","year":"1990","journal-title":"Lancet"},{"key":"2019041121320420100_R51","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0015-0282(98)00007-7","article-title":"Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function.","volume":"69","author":"Okon","year":"1998","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0015-0282(16)58017-0","article-title":"Polycystic ovary syndrome: pathophysiology and outcome with in vitro fertilization.","volume":"65","author":"Buyalos","year":"1996","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R53","first-page":"312","article-title":"Polycystic ovary disease. A risk factor for gestational diabetes?","volume":"40","author":"Lanzone","year":"1995","journal-title":"J Reprod Med"},{"key":"2019041121320420100_R54","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/humrep\/16.2.226","article-title":"Obstetric outcome in women with polycystic ovarian syndrome.","volume":"16","author":"Mikola","year":"2001","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R55","first-page":"2591","article-title":"Metabolic and steroidogenic alterations related to increased frequency of polycystic ovaries in women with a history of gestational diabetes.","volume":"86","author":"Koivunen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R56","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1210\/jcem.83.4.4707","article-title":"High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus.","volume":"83","author":"Holte","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R57","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0029-7844(98)00133-1","article-title":"Polycystic ovaries in women with gestational diabetes.","volume":"92","author":"Anttila","year":"1998","journal-title":"Obstet Gynecol"},{"key":"2019041121320420100_R58","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1046\/j.1365-2265.2000.01123.x","article-title":"The prevalence of polycystic ovaries in women with a history of gestational diabetes.","volume":"53","author":"Kousta","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041121320420100_R59","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1479-828X.2000.tb03167.x","article-title":"Prevalence of gestational diabetes mellitus in polycystic ovarian syndrome (PCOS) patients pregnant after ovulation induction with gonadotrophins.","volume":"40","author":"Vollenhoven","year":"2000","journal-title":"Aust NZ J Obstet Gynaecol"},{"key":"2019041121320420100_R60","first-page":"303","article-title":"Association between polycystic ovary syndrome and glucose intolerance during pregnancy.","volume":"6","author":"Lesser","year":"1997","journal-title":"J Matern Fetal Med"},{"key":"2019041121320420100_R61","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/humrep\/13.3.542","article-title":"Endocrino-metabolic features in women with polycystic ovary syndrome during pregnancy.","volume":"13","author":"Paradisi","year":"1998","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R62","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0301-2115(97)00164-4","article-title":"Higher risk of preeclampsia in the polycystic ovary syndrome. A case control study.","volume":"76","author":"de Vries","year":"1998","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2019041121320420100_R63","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0028-2243(82)90097-1","article-title":"High incidence of preeclamptic toxemia in patients with polycystic ovarian disease.","volume":"14","author":"Diamant","year":"1982","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2019041121320420100_R64","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1056\/NEJM198903163201105","article-title":"Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance.","volume":"320","author":"Zavaroni","year":"1989","journal-title":"N Engl J Med"},{"key":"2019041121320420100_R65","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1210\/jcem-61-5-946","article-title":"Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome.","volume":"61","author":"Wild","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R66","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0015-0282(02)03111-4","article-title":"Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus.","volume":"77","author":"Ovalle","year":"2002","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R67","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/humupd\/7.6.522","article-title":"Polycystic ovary syndrome and cancer.","volume":"7","author":"Balen","year":"2001","journal-title":"Hum Reprod Update"},{"key":"2019041121320420100_R68","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0889-8545(05)70189-3","article-title":"Cardiovascular risk in women with polycystic ovary syndrome.","volume":"28","author":"Talbott","year":"2001","journal-title":"Obstet Gynecol Clin North Am"},{"key":"2019041121320420100_R69","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0889-8529(05)70079-7","article-title":"Cardiovascular consequences of polycystic ovary syndrome.","volume":"28","author":"Amowitz","year":"1999","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2019041121320420100_R70","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0889-8529(05)70069-4","article-title":"The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks.","volume":"28","author":"Solomon","year":"1999","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2019041121320420100_R71","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1055\/s-2007-1016293","article-title":"Metabolic aspects of polycystic ovary syndrome.","volume":"15","author":"Wild","year":"1997","journal-title":"Semin Reprod Endocrinol"},{"key":"2019041121320420100_R72","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/humupd\/8.3.231","article-title":"Long-term health consequences of PCOS.","volume":"8","author":"Wild","year":"2002","journal-title":"Hum Reprod Update"},{"key":"2019041121320420100_R73","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0002-9149(99)00356-2","article-title":"Insulin resistance and systemic hypertension.","volume":"84","author":"Osei","year":"1999","journal-title":"Am J Cardiol"},{"key":"2019041121320420100_R74","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0015-0282(16)54892-4","article-title":"Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long term follow-up focusing on natural history and circulating hormones.","volume":"57","author":"Dahlgren","year":"1992","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R75","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0015-0282(16)56575-3","article-title":"Hemostatic and metabolic variables in women with polycystic ovary syndrome.","volume":"61","author":"Dahlgren","year":"1994","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R76","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/humrep\/15.4.785","article-title":"Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome.","volume":"15","author":"Cibula","year":"2000","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R77","first-page":"508","article-title":"Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance.","volume":"75","author":"Zimmermann","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R78","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/oxfordjournals.humrep.a019028","article-title":"Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state?","volume":"11","author":"Holte","year":"1996","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R79","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1056\/NEJM198708063170605","article-title":"Insulin resistance in essential hypertension.","volume":"317","author":"Ferrarini","year":"1987","journal-title":"N Engl J Med"},{"key":"2019041121320420100_R80","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1210\/jcem-66-3-580","article-title":"Resistance to insulin stimulated glucose uptake in patients with hypertension.","volume":"66","author":"Shen","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R81","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/009127009203200607","article-title":"Insulin resistance, hyperinsulinemia, dyslipidemia, hypertension, and accelerated atherosclerosis.","volume":"32","author":"Sowers","year":"1992","journal-title":"J Clin Pharmacol"},{"key":"2019041121320420100_R82","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0015-0282(16)48142-2","article-title":"Lipid metabolism in women with polycystic ovary syndrome: possible implications for an increased risk of coronary heart disease.","volume":"42","author":"Mattson","year":"1984","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R83","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2265.1992.tb02295.x","article-title":"Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome.","volume":"37","author":"Conway","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041121320420100_R84","first-page":"3389","article-title":"Altered composition of high density lipoproteins in women with the polycystic ovary syndrome.","volume":"82","author":"Rajkhowa","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R85","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1161\/01.ATV.15.7.821","article-title":"Coronary heart disease risk factors in women with polycystic ovary syndrome.","volume":"15","author":"Talbott","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2019041121320420100_R86","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1365-2265.1996.674495.x","article-title":"Dyslipidemia is associated with insulin resistance in women with polycystic ovaries.","volume":"44","author":"Robinson","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041121320420100_R87","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2265.1994.tb02577.x","article-title":"Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables.","volume":"41","author":"Holte","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041121320420100_R88","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1055\/s-0038-1657607","article-title":"PAI-1, obesity, insulin resistance and risk of cardiovascular events.","volume":"78","author":"Juhan-Vague","year":"1997","journal-title":"Thromb Haemost"},{"key":"2019041121320420100_R89","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0015-0282(97)00486-X","article-title":"The plasminogen activator system in women with polycystic ovary syndrome.","volume":"69","author":"Atiomo","year":"1998","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R90","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1046\/j.1365-2265.1996.00863.x","article-title":"Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) in lean women with and without polycystic ovary syndrome.","volume":"45","author":"Sampson","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041121320420100_R91","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0015-0282(16)53699-1","article-title":"Clinical signs of androgen excess as risk factors for coronary artery artery disease.","volume":"54","author":"Wild","year":"1990","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R92","doi-asserted-by":"crossref","first-page":"32","DOI":"10.7326\/0003-4819-126-1-199701010-00005","article-title":"Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization.","volume":"126","author":"Birdsall","year":"1997","journal-title":"Ann Intern Med"},{"key":"2019041121320420100_R93","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0015-0282(00)00695-6","article-title":"Do polycystic-appearing ovaries affect the risk of cardiovascular disease among women with polycystic ovary syndrome?","volume":"74","author":"Loucks","year":"2000","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R94","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3109\/00016349209006227","article-title":"Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women.","volume":"71","author":"Dahlgren","year":"1992","journal-title":"Acta Obstet Gynaecol Scand"},{"key":"2019041121320420100_R95","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0895-4356(98)00035-3","article-title":"Mortality of women with polycystic ovary syndrome at long-term follow-up.","volume":"51","author":"Pierpoint","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"2019041121320420100_R96","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1365-2265.2000.01000.x","article-title":"Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study.","volume":"52","author":"Wild","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041121320420100_R97","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S0002-9378(96)70665-8","article-title":"Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study.","volume":"174","author":"Guzick","year":"1996","journal-title":"Am J Obstet Gynecol"},{"key":"2019041121320420100_R98","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1161\/01.ATV.20.11.2414","article-title":"Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women.","volume":"20","author":"Talbott","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2019041121320420100_R99","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1056\/NEJM199312303292703","article-title":"Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus.","volume":"329","author":"Lillioja","year":"1993","journal-title":"N Engl J Med"},{"key":"2019041121320420100_R100","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","article-title":"Banting lecture 1988. Role of insulin resistance in human disease.","volume":"37","author":"Reaven","year":"1988","journal-title":"Diabetes"},{"key":"2019041121320420100_R101","first-page":"1241","article-title":"Defects in \u03b2-cell function in functional ovarian hyperandrogenism.","volume":"76","author":"O\u2019Meara","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R102","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1749-6632.1993.tb43854.x","article-title":"Insulin resistance in polycystic ovary syndrome.","volume":"687","author":"Dunaif","year":"1993","journal-title":"Ann NY Acad Sci"},{"key":"2019041121320420100_R103","first-page":"165","article-title":"Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.","volume":"84","author":"Legro","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R104","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/humrep\/16.3.556","article-title":"Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population.","volume":"16","author":"Elting","year":"2001","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R105","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0026-0495(98)90234-7","article-title":"Impact of family history of diabetes on the assessment of \u03b2-cell function.","volume":"47","author":"Alford","year":"1998","journal-title":"Metabolism"},{"key":"2019041121320420100_R106","first-page":"165","article-title":"Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.","volume":"84","author":"Legro","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R107","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1365-2265.2000.00884.x","article-title":"The prevalence of polycystic ovaries in women with type 2 diabetes mellitus.","volume":"52","author":"Conn","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041121320420100_R108","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.2337\/diacare.24.6.1050","article-title":"Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes.","volume":"24","author":"Peppard","year":"2001","journal-title":"Diabetes Care"},{"key":"2019041121320420100_R109","first-page":"659","article-title":"Endometrial hyperplasia in young women.","volume":"36","author":"Chamlian","year":"1970","journal-title":"Obstet Gynecol"},{"key":"2019041121320420100_R110","first-page":"403","article-title":"Chronic anovulation syndrome and associated neoplasia.","volume":"61","author":"Coulam","year":"1983","journal-title":"Obstet Gynecol"},{"key":"2019041121320420100_R111","first-page":"325","article-title":"Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome.","volume":"98","author":"Cheung","year":"2001","journal-title":"Obstet Gynecol"},{"key":"2019041121320420100_R112","first-page":"2572","article-title":"Serum and urinary androgens and risk of breast cancer in postmenopausal women.","volume":"51","author":"Secreto","year":"1991","journal-title":"Cancer Res"},{"key":"2019041121320420100_R113","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/oxfordjournals.aje.a116156","article-title":"Polycystic ovaries and the risk of breast cancer.","volume":"134","author":"Gammon","year":"1991","journal-title":"Am J Epidemiol"},{"key":"2019041121320420100_R114","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<494::AID-CNCR10>3.0.CO;2-Z","article-title":"Association of Stein-Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa.","volume":"79","author":"Anderson","year":"1997","journal-title":"Cancer"},{"key":"2019041121320420100_R115","first-page":"193","article-title":"Insulin resistance: the clinical spectrum.","volume":"6","author":"Mantzoros","year":"1995","journal-title":"Adv Endocrinol Metab"},{"key":"2019041121320420100_R116","first-page":"51","article-title":"Le virilisme plaire et son association a l\u2019insuffisance glycolytique (diabete des femmes a barbe).","volume":"86","author":"Achard","year":"1921","journal-title":"Bull Acad Natl Med"},{"key":"2019041121320420100_R117","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1056\/NEJM197604012941401","article-title":"The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man.","volume":"294","author":"Kahn","year":"1976","journal-title":"N Engl J Med"},{"key":"2019041121320420100_R118","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1210\/jcem-50-1-113","article-title":"Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease.","volume":"50","author":"Burghen","year":"1980","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R119","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1210\/jcem-57-2-356","article-title":"Insulin resistance in nonobese patients with polycystic ovarian disease.","volume":"57","author":"Chang","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R120","first-page":"577","article-title":"Cellular mechanisms of insulin resistance in polycystic ovarian syndrome.","volume":"75","author":"Ciaraldi","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R121","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/0026-0495(94)90013-2","article-title":"Severe impairment of insulin action in adipocytes from amenorrhoeic subjects with polycystic ovary syndrome.","volume":"43","author":"Marsden","year":"1994","journal-title":"Metabolism"},{"key":"2019041121320420100_R122","first-page":"2854","article-title":"Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common distinct features.","volume":"81","author":"Morales","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R123","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0015-0282(16)55249-2","article-title":"Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations.","volume":"58","author":"Dale","year":"1992","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R124","first-page":"1636","article-title":"Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary sindrome.","volume":"77","author":"Ovesen","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R125","first-page":"1052","article-title":"Enhanced insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance.","volume":"78","author":"Holte","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R126","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0015-0282(99)00184-3","article-title":"Insulin, androgens and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders.","volume":"71","author":"Acien","year":"1999","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R127","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/humrep\/15.6.1266","article-title":"Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome.","volume":"15","author":"Morin-Papunen","year":"2000","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R128","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1172\/JCI118064","article-title":"Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus.","volume":"96","author":"Ehrmann","year":"1995","journal-title":"J Clin Invest"},{"key":"2019041121320420100_R129","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2337\/diacare.22.1.141","article-title":"Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.","volume":"22","author":"Ehrmann","year":"1999","journal-title":"Diabetes Care"},{"key":"2019041121320420100_R130","first-page":"4426","article-title":"Insulin sensitivity and its measurement. Structural commonalities among the methods.","volume":"85","author":"Radziuk","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R131","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/BF00280882","article-title":"Continuous infusion of glucose with model assessment: measurement of insulin resistance and \u03b2-cell function in man.","volume":"28","author":"Hosker","year":"1985","journal-title":"Diabetologia"},{"key":"2019041121320420100_R132","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1210\/jcem.85.7.6661","article-title":"Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.","volume":"85","author":"Katz","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R133","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2337\/diab.15.12.901","article-title":"Reproducibility of the oral glucose tolerance test and the rice-meal test in mild diabetes.","volume":"15","author":"Kosaka","year":"1966","journal-title":"Diabetes"},{"key":"2019041121320420100_R134","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1172\/JCI112886","article-title":"Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp.","volume":"79","author":"Bergman","year":"1987","journal-title":"J Clin Invest"},{"key":"2019041121320420100_R135","first-page":"2694","article-title":"A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome.","volume":"83","author":"Legro","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R136","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0140-6736(05)62350-1","article-title":"Efficacy of troglitazone measured by insulin resistance index.","volume":"350","author":"Nagasaka","year":"1997","journal-title":"Lancet"},{"key":"2019041121320420100_R137","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/humrep\/15.10.2098","article-title":"Prediction models for insulin resistance in the polycystic ovary syndrome.","volume":"15","author":"Gennarelli","year":"2000","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R138","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2265.1993.tb02376.x","article-title":"The relationship of insulin insensitivity to menstrual pattern with hyperandrogenism and polycystic ovaries.","volume":"39","author":"Robinson","year":"1993","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041121320420100_R139","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1067\/mob.2000.107627","article-title":"Induction of ovulation in infertile women with hyperandrogenism and insulin resistance.","volume":"183","author":"Barbieri","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"2019041121320420100_R140","first-page":"322","article-title":"Association of insulin resistance with hyperandrogenia in women.","volume":"54","author":"Pugeat","year":"2000","journal-title":"Horm Res"},{"key":"2019041121320420100_R141","first-page":"614","article-title":"Decreased insulin sensitivity in prepubertal girls with premature adrenarche and acanthosis nigricans.","volume":"80","author":"Oppenheimer","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R142","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1365-2265.1993.tb02419.x","article-title":"Clinical implications of hyperinsulinaemia in women.","volume":"39","author":"Conway","year":"1993","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041121320420100_R143","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/pgmj.66.777.536","article-title":"Acanthosis nigricans in obese women with the polycystic ovary syndrome: disease spectrum not distinct entity.","volume":"66","author":"Conway","year":"1990","journal-title":"Postgrad Med J"},{"key":"2019041121320420100_R144","first-page":"972","article-title":"The insulin receptor and its cellular targets.","volume":"86","author":"Kido","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R145","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/edrv.20.4.0374","article-title":"The insulin-related ovarian regulatory system in health and disease.","volume":"20","author":"Poretsky","year":"1999","journal-title":"Endocr Rev"},{"key":"2019041121320420100_R146","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1210\/jcem-61-4-728","article-title":"Distribution and characterization of insulin and insulin-like growth factor I receptors in normal human ovary.","volume":"61","author":"Poretsky","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R147","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1507\/endocrj.40.715","article-title":"Insulin receptor expression in follicular and stromal compartments of the human ovary over the course of follicular growth, regression and atresia.","volume":"40","author":"Samoto","year":"1993","journal-title":"Endocr J"},{"key":"2019041121320420100_R148","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2337\/diab.34.2.101","article-title":"Acanthosis nigricans in obese women with hyperandrogenism. Characterization of an insulin-resistant state distinct from the type A and B syndromes.","volume":"34","author":"Flier","year":"1985","journal-title":"Diabetes"},{"key":"2019041121320420100_R149","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1210\/jcem-64-5-1066","article-title":"Evidence for insulin resistance in nonobese patients with polycystic ovarian disease.","volume":"64","author":"Jialal","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R150","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1046\/j.1365-2265.2001.01303.x","article-title":"Tissue insulin sensitivity and body weight in polycystic ovary syndrome.","volume":"55","author":"Marsden","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041121320420100_R151","first-page":"3110","article-title":"Selective insulin resistance in the polycystic ovary syndrome.","volume":"84","author":"Book","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R152","first-page":"197","article-title":"Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes.","volume":"264","author":"Rosenbaum","year":"1993","journal-title":"Am J Physiol"},{"key":"2019041121320420100_R153","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0002-9343(99)80057-6","article-title":"Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus.","volume":"98","author":"Dunaif","year":"1995","journal-title":"Am J Med"},{"key":"2019041121320420100_R154","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1172\/JCI118126","article-title":"Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome.","volume":"96","author":"Dunaif","year":"1995","journal-title":"J Clin Invest"},{"key":"2019041121320420100_R155","doi-asserted-by":"crossref","first-page":"10619","DOI":"10.1073\/pnas.92.23.10619","article-title":"Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome.","volume":"92","author":"Zhang","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019041121320420100_R156","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1152\/ajpendo.2001.281.2.E392","article-title":"Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS).","volume":"281","author":"Dunaif","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2019041121320420100_R157","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2337\/diab.46.4.541","article-title":"New insights into the role and mechanism of glycogen synthase activation by insulin.","volume":"46","author":"Lawrence Jr","year":"1997","journal-title":"Diabetes"},{"key":"2019041121320420100_R158","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0015-0282(00)01769-6","article-title":"Altered autophosphorylation of the insulin receptor in the ovary of a woman with polycystic ovary syndrome.","volume":"75","author":"Moran","year":"2001","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R159","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S0015-0282(00)00688-9","article-title":"Expression of insulin-receptor substrate-1 and -2 in ovaries from women with insulin resistance and from controls.","volume":"74","author":"Wu","year":"2000","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R160","first-page":"1421","article-title":"Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity.","volume":"82","author":"Ciaraldi","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R161","first-page":"1291","article-title":"Molecular defects of insulin action in the polycystic ovary syndrome: possible tissue specificity.","volume":"13","author":"Ciaraldi","year":"2000","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2019041121320420100_R162","first-page":"2001","article-title":"Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system.","volume":"83","author":"Nestler","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R163","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1210\/jcem-59-4-809","article-title":"Specific insulin binding sites in human ovary.","volume":"59","author":"Poretsky","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R164","first-page":"302","article-title":"Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries.","volume":"81","author":"Willis","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R165","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0015-0282(16)55675-1","article-title":"Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin.","volume":"59","author":"Bergh","year":"1993","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R166","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0015-0282(97)00473-1","article-title":"Insulin and insulin-like growth factor I stimulate the proliferation of human ovarian theca-interstitial cells.","volume":"69","author":"Duleba","year":"1998","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R167","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1210\/endo-123-2-733","article-title":"Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells.","volume":"123","author":"Cara","year":"1988","journal-title":"Endocrinology"},{"key":"2019041121320420100_R168","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1210\/endo-122-4-1603","article-title":"Somatomedin-C\/insulin-like growth factor I as an enhancer of androgen biosynthesis by cultured rat ovarian cells.","volume":"122","author":"Hernandez","year":"1988","journal-title":"Endocrinology"},{"key":"2019041121320420100_R169","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1677\/joe.0.1450491","article-title":"Effects of inhibin-related peptides and oestradiol on androstenedione and progesterone secretion by bovine theca cells in vitro.","volume":"145","author":"Wrathall","year":"1995","journal-title":"J Endocrinol"},{"key":"2019041121320420100_R170","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0039-128X(96)00223-1","article-title":"Induction of steroidogenic enzyme genes by insulin and IGF-I in cultured adult human adrenocortical cells.","volume":"62","author":"Kristiansen","year":"1997","journal-title":"Steroids"},{"key":"2019041121320420100_R171","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1210\/edrv-6-3-400","article-title":"Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function.","volume":"6","author":"Adashi","year":"1985","journal-title":"Endocr Rev"},{"key":"2019041121320420100_R172","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/oxfordjournals.humrep.a137080","article-title":"Plasma androgens and oestradiol during oral glucose tolerance test in patients with polycystic ovaries.","volume":"5","author":"Tiitinen","year":"1990","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R173","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0015-0282(16)54172-7","article-title":"Androgen responses to acutely increased endogenous insulin levels in hyperandrogenic and normal cycling women.","volume":"55","author":"Elkind-Hirsch","year":"1991","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R174","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1210\/jcem-72-4-883","article-title":"Effect of acute physiological elevations of insulin on circulating androgen levels in nonobese women.","volume":"72","author":"Diamond","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R175","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1210\/jcem-64-1-180","article-title":"The effects of hyperinsulinemia on serum testosterone, progesterone, dehydroepiandrosterone sulfate, and cortisol levels in normal women and in a woman with hyperandrogenism, insulin resistance, and acanthosis nigricans.","volume":"64","author":"Nestler","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R176","first-page":"921","article-title":"Hyperinsulinemia and hyperandrogenemia: in vivo androgen response to insulin infusion.","volume":"69","author":"Stuart","year":"1987","journal-title":"Obstet Gynecol"},{"key":"2019041121320420100_R177","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/0022-4731(88)90344-5","article-title":"Androgen levels during sequential insulin euglycemic clamp studies in patients with polycystic ovary disease.","volume":"31","author":"Micic","year":"1988","journal-title":"J Steroid Biochem"},{"key":"2019041121320420100_R178","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1172\/JCI113864","article-title":"Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with the polycystic ovary syndrome.","volume":"83","author":"Dunaif","year":"1989","journal-title":"J Clin Invest"},{"key":"2019041121320420100_R179","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1210\/jcem-72-6-1308","article-title":"Insulin resistance and hyperinsulinemia induce hyperandrogenism in a young type B insulin-resistant female.","volume":"72","author":"DeClue","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R180","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1210\/jcem-68-6-1027","article-title":"Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome.","volume":"68","author":"Nestler","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R181","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/0140-6736(90)92270-R","article-title":"Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndrome.","volume":"336","author":"Prelevic","year":"1990","journal-title":"Lancet"},{"key":"2019041121320420100_R182","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/humrep\/16.10.2066","article-title":"Clinical, endocrine and metabolic effects of acarbose, an \u03b1-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance.","volume":"16","author":"Ciotta","year":"2001","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R183","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJM199608293350902","article-title":"Decreases in ovarian cytochrome P450c17 \u03b1 activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.","volume":"335","author":"Nestler","year":"1996","journal-title":"N Engl J Med"},{"key":"2019041121320420100_R184","first-page":"4075","article-title":"Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 \u03b1 activity and serum androgens.","volume":"82","author":"Nestler","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R185","first-page":"3299","article-title":"The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.","volume":"81","author":"Dunaif","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R186","first-page":"3526","article-title":"Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche.","volume":"85","author":"Ibanez","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R187","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1530\/eje.0.1440619","article-title":"The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome.","volume":"144","author":"Vrbikova","year":"2001","journal-title":"Eur J Endocrinol"},{"key":"2019041121320420100_R188","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev.ph.49.030187.002003","article-title":"Insulin in the brain.","volume":"49","author":"Baskin","year":"1987","journal-title":"Annu Rev Physiol"},{"key":"2019041121320420100_R189","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0301-0082(91)90015-S","article-title":"Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects.","volume":"36","author":"Unger","year":"1991","journal-title":"Prog Neurobiol"},{"key":"2019041121320420100_R190","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1126\/science.289.5487.2122","article-title":"Role of brain insulin receptor in control of body weight and reproduction.","volume":"289","author":"Bruning","year":"2000","journal-title":"Science"},{"key":"2019041121320420100_R191","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1172\/JCI112654","article-title":"Insulin regulation of rat growth hormone gene transcription.","volume":"78","author":"Yamashita","year":"1986","journal-title":"J Clin Invest"},{"key":"2019041121320420100_R192","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1210\/endo-108-4-1441","article-title":"Insulin enhancement of luteinizing hormone and follicle stimulating hormone release by cultured pituitary cells.","volume":"108","author":"Adashi","year":"1981","journal-title":"Endocrinology"},{"key":"2019041121320420100_R193","first-page":"3728","article-title":"Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity.","volume":"82","author":"Arroyo","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R194","first-page":"2248","article-title":"Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome.","volume":"82","author":"Taylor","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R195","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0029-7844(97)00296-2","article-title":"Menstrual cyclicity after metformin therapy in polycystic ovary syndrome.","volume":"90","author":"Velazquez","year":"1997","journal-title":"Obstet Gynecol"},{"key":"2019041121320420100_R196","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1093\/humrep\/14.12.2963","article-title":"Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea.","volume":"14","author":"Pirwany","year":"1999","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R197","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1210\/jcem.86.8.7756","article-title":"Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism.","volume":"86","author":"Ibanez","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R198","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1530\/eje.0.1440509","article-title":"Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome.","volume":"144","author":"Kowalska","year":"2001","journal-title":"Eur J Endocrinol"},{"key":"2019041121320420100_R199","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1210\/jcem-67-3-460","article-title":"Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin.","volume":"67","author":"Plymate","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R200","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/0026-0495(88)90091-1","article-title":"The relationship of sex hormones to hyperinsulinemia and hyperglycemia.","volume":"37","author":"Haffner","year":"1988","journal-title":"Metabolism"},{"key":"2019041121320420100_R201","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0015-0282(16)60791-4","article-title":"The relationship of insulin to sex hormone-binding globulin: role of adiposity.","volume":"52","author":"Peiris","year":"1989","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R202","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1210\/jcem-72-1-83","article-title":"A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.","volume":"72","author":"Nestler","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R203","first-page":"283","article-title":"Interrelation between plasma sex hormone-binding globulin and plasma insulin in healthy adult women: the telecom study.","volume":"76","author":"Preziosi","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R204","first-page":"2108","article-title":"Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.","volume":"82","author":"Ehrmann","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R205","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1210\/jcem-66-2-266","article-title":"Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein.","volume":"66","author":"Suikkari","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R206","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3181\/00379727-216-44182","article-title":"Insulin-like growth factor binding protein-1: recent findings and new directions.","volume":"216","author":"Lee","year":"1997","journal-title":"Proc Soc Exp Biol Med"},{"key":"2019041121320420100_R207","first-page":"3030","article-title":"Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome.","volume":"84","author":"Thierry van Dessel","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R208","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/oxfordjournals.humrep.a137577","article-title":"The role of insulin-like growth factor-1 (IGF-1) and IGF binding protein-1 (IGFBP-1) in the pathogenesis of polycystic ovary syndrome.","volume":"7","author":"Homburg","year":"1992","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R209","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2265.1990.tb03897.x","article-title":"Effects of luteinizing hormone, insulin, insulin-like growth factor-I and insulin-like growth factor small binding protein 1 in the polycystic ovary syndrome.","volume":"33","author":"Conway","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041121320420100_R210","first-page":"2854","article-title":"Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.","volume":"81","author":"Morales","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R211","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1210\/jcem-70-4-894","article-title":"The effects of insulin and insulin-like growth factors-I and -II on estradiol production by granulosa cells of polycystic ovaries.","volume":"70","author":"Erickson","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R212","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/0002-9378(84)90769-5","article-title":"Aromatase activity in human granulosa cells during follicular development and the modulation by follicle-stimulating hormone and insulin.","volume":"148","author":"Garzo","year":"1984","journal-title":"Am J Obstet Gynecol"},{"key":"2019041121320420100_R213","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1210\/jcem-69-4-716","article-title":"Insulin-like growth factor-I regulates aromatase activity in human granulosa and granulosa luteal cells.","volume":"69","author":"Erickson","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R214","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1210\/mend.11.8.9956","article-title":"Regulation of gonadotropin-releasing hormone (GnRH) gene expression by insulin-like growth factor I in a cultured GnRH-expressing neuronal cell line.","volume":"11","author":"Zhen","year":"1997","journal-title":"Mol Endocrinol"},{"key":"2019041121320420100_R215","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1210\/endo.139.3.5852","article-title":"Insulin-like growth factor-I effects on gonadotropin-releasing hormone biosynthesis in GT1\u20137 cells.","volume":"139","author":"Longo","year":"1998","journal-title":"Endocrinology"},{"key":"2019041121320420100_R216","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1530\/acta.0.1250227","article-title":"Effect of insulin-like growth factor I on gonadotropin release from the hypothalamus-pituitary axis in vitro.","volume":"125","author":"Kanematsu","year":"1991","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2019041121320420100_R217","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1210\/jcem.85.4.6560","article-title":"Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein I in polycystic ovary syndrome.","volume":"85","author":"De Leo","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R218","first-page":"1126","article-title":"Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome.","volume":"86","author":"Jakubowicz","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R219","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1210\/edrv-9-3-295","article-title":"Molecular biology of steroid hormone synthesis.","volume":"9","author":"Miller","year":"1988","journal-title":"Endocr Rev"},{"key":"2019041121320420100_R220","first-page":"3892","article-title":"Insulin-like growth factors enhance steroidogenic enzyme and corticotropin receptor messenger ribonucleic acid levels and corticotropin steroidogenic responsiveness in cultured human adrenocortical cells.","volume":"81","author":"l\u2019Allemand","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R221","first-page":"1390","article-title":"Insulin-like growth factors augment steroid production and expression of steroidogenic enzymes in human fetal adrenal cortical cells: implications for adrenal androgen regulation.","volume":"82","author":"Mesiano","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R222","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1210\/endo-114-3-767","article-title":"Permissive effect of insulin on the adenosine 3\u2032,5\u2032-monophosphate-dependent up-regulation of low density lipoprotein receptors and the stimulation of steroid release in bovine adrenal cortical cells.","volume":"114","author":"Ill","year":"1984","journal-title":"Endocrinology"},{"key":"2019041121320420100_R223","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0960-0760(92)90219-9","article-title":"Mechanisms of insulin inhibition of ACTH-stimulated steroid secretion by cultured bovine adrenocortical cells.","volume":"41","author":"Klein","year":"1992","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2019041121320420100_R224","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0026-0495(94)90202-X","article-title":"Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men.","volume":"43","author":"Haffner","year":"1994","journal-title":"Metabolism"},{"key":"2019041121320420100_R225","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0140-6736(67)91654-6","article-title":"A possible interrelation between glucose-6-phosphate dehydrogenase and dehydroepiandrosterone in obesity.","volume":"2","author":"Lopez","year":"1967","journal-title":"Lancet"},{"key":"2019041121320420100_R226","first-page":"881","article-title":"Insulin infusion amplifies 17 \u03b1-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity.","volume":"81","author":"Moghetti","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R227","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0015-0282(16)55220-0","article-title":"Differential androgen response to adrenocorticotropic hormone stimulation in polycystic ovarian syndrome: relationship with insulin secretion.","volume":"58","author":"Lanzone","year":"1992","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R228","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0015-0282(99)00407-0","article-title":"Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome.","volume":"72","author":"la Marca","year":"1999","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R229","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1172\/JCI117252","article-title":"Mechanisms of fatty acid-induced inhibition of glucose uptake.","volume":"93","author":"Boden","year":"1994","journal-title":"J Clin Invest"},{"key":"2019041121320420100_R230","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1172\/JCI118742","article-title":"Mechanism of free fatty acid-induced insulin resistance in humans.","volume":"97","author":"Roden","year":"1996","journal-title":"J Clin Invest"},{"key":"2019041121320420100_R231","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1172\/JCI117899","article-title":"The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase.","volume":"95","author":"Kern","year":"1995","journal-title":"J Clin Invest"},{"key":"2019041121320420100_R232","first-page":"2907","article-title":"Tumor necrosis factor-\u03b1 in sera of obese patients: fall with weight loss.","volume":"83","author":"Dandona","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R233","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1046\/j.1365-2796.1999.00490.x","article-title":"The role of TNF\u03b1 and TNF receptors in obesity and insulin resistance.","volume":"245","author":"Hotamisligil","year":"1999","journal-title":"J Intern Med"},{"key":"2019041121320420100_R234","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0026-0495(99)90100-2","article-title":"Elevated serum levels of tumor necrosis factor \u03b1 in normal-weight women with polycystic ovary syndrome.","volume":"48","author":"Gonzalez","year":"1999","journal-title":"Metabolism"},{"key":"2019041121320420100_R235","first-page":"3761","article-title":"TNF-\u03b1 and hyperandrogenism: a clinical, biochemical, and molecular genetic study.","volume":"86","author":"Escobar-Morreale","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R236","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1056\/NEJM199508313330903","article-title":"Metabolic effects of metformin in non-insulin dependent diabetes mellitus.","volume":"333","author":"Stumvoll","year":"1995","journal-title":"N Engl J Med"},{"key":"2019041121320420100_R237","first-page":"4059","article-title":"Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.","volume":"81","author":"Cusi","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R238","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/0306-3623(93)90411-P","article-title":"Metformin\u2014an update.","volume":"24","author":"Bailey","year":"1993","journal-title":"Gen Pharmacol"},{"key":"2019041121320420100_R239","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1016\/0006-2952(88)90617-X","article-title":"Inhibition of hepatic gluconeogenesis by metformin: synergism with insulin.","volume":"37","author":"Wollen","year":"1988","journal-title":"Biochem Pharmacol"},{"key":"2019041121320420100_R240","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jcem-73-6-1294","article-title":"Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.","volume":"73","author":"De Fronzo","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R241","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2337\/diacare.21.8.1301","article-title":"Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin.","volume":"21","author":"Abbasi","year":"1998","journal-title":"Diabetes Care"},{"key":"2019041121320420100_R242","first-page":"585","article-title":"Pathophysiology and pharmacological treatment of insulin resistance.","volume":"21","author":"Matthaei","year":"2000","journal-title":"Endocr Rev"},{"key":"2019041121320420100_R243","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJM199508313330902","article-title":"The Multicenter Metformin Study Group: efficacy of metformin in patients with non-insulin dependent diabetes mellitus.","volume":"333","author":"De Fronzo","year":"1995","journal-title":"N Engl J Med"},{"key":"2019041121320420100_R244","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s001250051172","article-title":"Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes.","volume":"42","author":"Makimattila","year":"1999","journal-title":"Diabetologia"},{"key":"2019041121320420100_R245","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0006-2952(01)00679-7","article-title":"Effect of metformin on fatty acid and glucose metabolism in freshly isolated hepatocytes and on specific gene expression in cultured hepatocytes.","volume":"62","author":"Fulgencio","year":"2001","journal-title":"Biochem Pharmacol"},{"key":"2019041121320420100_R246","first-page":"346","article-title":"Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus.","volume":"12","author":"Prager","year":"1986","journal-title":"Diabetes Metab"},{"key":"2019041121320420100_R247","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2337\/diab.41.3.354","article-title":"Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM.","volume":"41","author":"Widen","year":"1992","journal-title":"Diabetes"},{"key":"2019041121320420100_R248","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1172\/JCI116005","article-title":"Glucose transport in human skeletal muscle cells in culture. Stimulation by insulin and metformin.","volume":"90","author":"Sarabia","year":"1992","journal-title":"J Clin Invest"},{"key":"2019041121320420100_R249","first-page":"34","article-title":"Evidence that metformin increases insulin-stimulated glucose transport by potentiating insulin-induced translocation of glucose transporters from an intracellular pool to the cell surface in rat adipocytes.","volume":"26","author":"Matthaei","year":"1992","journal-title":"Horm Metab Res Suppl"},{"key":"2019041121320420100_R250","first-page":"159","article-title":"Metformin increases insulin-stimulated glucose transport in insulin-resistant human skeletal muscle.","volume":"17","author":"Galuska","year":"1987","journal-title":"Diabetes Metab"},{"key":"2019041121320420100_R251","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2796.1994.tb01083.x","article-title":"Metformin and metoprolol CR treatment in non-obese men.","volume":"235","author":"Landin","year":"1994","journal-title":"J Intern Med"},{"key":"2019041121320420100_R252","first-page":"25","article-title":"Effects of metformin on intact and des 31,32 proinsulin in subjects with non-insulin-dependent diabetes.","volume":"11","author":"Nagi","year":"1994","journal-title":"Diabet Med"},{"key":"2019041121320420100_R253","first-page":"150","article-title":"The effect of metformin on the metabolic anomalies associated with android type body fat distribution. Results of the BIGPRO trial.","volume":"43","author":"Rudnichi","year":"1994","journal-title":"Diabetes"},{"key":"2019041121320420100_R254","first-page":"15","article-title":"Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes.","volume":"20","author":"Marena","year":"1994","journal-title":"Diabetes Metab"},{"key":"2019041121320420100_R255","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2337\/diacare.10.1.62","article-title":"Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes.","volume":"10","author":"Nosadini","year":"1987","journal-title":"Diabetes Care"},{"key":"2019041121320420100_R256","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2337\/diacare.13.6.696","article-title":"Cellular mechanism of action of metformin.","volume":"13","author":"Klip","year":"1990","journal-title":"Diabetes Care"},{"key":"2019041121320420100_R257","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0006-2952(97)00540-6","article-title":"Stimulation of the intracellular portion of the human insulin receptor by the antidiabetic drug metformin.","volume":"55","author":"Stith","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"2019041121320420100_R258","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0168-3659(00)00374-6","article-title":"Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation.","volume":"71","author":"Stepensky","year":"2001","journal-title":"J Control Release"},{"key":"2019041121320420100_R259","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2337\/diacare.15.6.755","article-title":"Biguanides and NIDDM.","volume":"15","author":"Bailey","year":"1992","journal-title":"Diabetes Care"},{"key":"2019041121320420100_R260","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM199801223380415","article-title":"Lactic acidosis in patients with diabetes treated with metformin.","volume":"338","author":"Misbin","year":"1998","journal-title":"N Engl J Med"},{"key":"2019041121320420100_R261","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0002-9343(98)00088-6","article-title":"Metformin-induced acute hepatitis.","volume":"104","author":"Babich","year":"1998","journal-title":"Am J Med"},{"key":"2019041121320420100_R262","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0015-0282(01)02825-4","article-title":"Effect of metformin on mouse embryo development.","volume":"76","author":"Bedaiwy","year":"2001","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R263","first-page":"3161","article-title":"Endocrine and metabolic effects of metformin vs. ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.","volume":"85","author":"Morin-Papunen","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R264","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0015-0282(16)58266-1","article-title":"Can metformin reduce insulin resistance in polycystic ovary syndrome?","volume":"65","author":"Acbay","year":"1996","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R265","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1056\/NEJM199806253382603","article-title":"Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.","volume":"338","author":"Nestler","year":"1998","journal-title":"N Engl J Med"},{"key":"2019041121320420100_R266","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0026-0495(97)90066-4","article-title":"Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.","volume":"46","author":"Velazquez","year":"1997","journal-title":"Metabolism"},{"key":"2019041121320420100_R267","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0015-0282(98)00011-9","article-title":"Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.","volume":"69","author":"Morin-Papunen","year":"1998","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R268","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1210\/jcem.85.8.6738","article-title":"Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.","volume":"85","author":"Pasquali","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R269","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/humrep\/16.8.1625","article-title":"Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial.","volume":"16","author":"Ng","year":"2001","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R270","first-page":"524","article-title":"Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome.","volume":"82","author":"Ehrmann","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R271","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.1365-2265.1999.00786.x","article-title":"The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.","volume":"51","author":"Unluhizarci","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041121320420100_R272","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/eje.0.1380269","article-title":"Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome.","volume":"138","author":"Diamanti-Kandarakis","year":"1998","journal-title":"Eur J Endocrinol"},{"key":"2019041121320420100_R273","first-page":"139","article-title":"Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.","volume":"85","author":"Moghetti","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R274","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/diab.42.11.1663","article-title":"Quantification of the relationship between insulin sensitivity and \u03b2-cell function in human subjects. Evidence for a hyperbolic function.","volume":"42","author":"Kahn","year":"1993","journal-title":"Diabetes"},{"key":"2019041121320420100_R275","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0026-0495(94)90209-7","article-title":"Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.","volume":"46","author":"Velazquez","year":"1994","journal-title":"Metabolism"},{"key":"2019041121320420100_R276","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0026-0495(99)90113-0","article-title":"Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome.","volume":"48","author":"Glueck","year":"1999","journal-title":"Metabolism"},{"key":"2019041121320420100_R277","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0015-0282(00)00501-X","article-title":"Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.","volume":"73","author":"Kolodziejczyk","year":"2000","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R278","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0015-0282(00)01675-7","article-title":"Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone.","volume":"75","author":"Vandermolen","year":"2001","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R279","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1365-2265.1997.2321049.x","article-title":"Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome.","volume":"47","author":"Gilling-Smith","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041121320420100_R280","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0015-0282(01)01975-6","article-title":"Metformin directly inhibits androgen production in human thecal cells.","volume":"76","author":"Attia","year":"2001","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R281","first-page":"274","article-title":"Changes in insulin receptor tyrosine kinase activity associated with metformin treatment of type 2 diabetes.","volume":"21","author":"Santos","year":"1995","journal-title":"Diabetes Metab"},{"key":"2019041121320420100_R282","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0015-0282(99)00208-3","article-title":"Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome.","volume":"72","author":"De Leo","year":"1999","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R283","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0015-0282(00)01666-6","article-title":"Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study.","volume":"75","author":"Glueck","year":"2001","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R284","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0015-0282(00)01766-0","article-title":"Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors.","volume":"75","author":"Stadtmauer","year":"2001","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R285","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1054-139X(01)00202-6","article-title":"Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS).","volume":"29","author":"Glueck","year":"2001","journal-title":"J Adolesc Health"},{"key":"2019041121320420100_R286","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0015-0282(01)02941-7","article-title":"Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome.","volume":"77","author":"Kocak","year":"2002","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R287","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1210\/jcem.87.2.8207","article-title":"Effects of metformin on early pregnancy loss in the polycystic ovary syndrome.","volume":"87","author":"Jakubowicz","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R288","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1210\/jcem.87.2.8261","article-title":"Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial.","volume":"87","author":"Fleming","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R289","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0015-0282(01)03202-2","article-title":"Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome.","volume":"77","author":"Glueck","year":"2002","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R290","first-page":"23","article-title":"Polycystic ovary syndrome. Insulin resistance and ovulatory responses to clomiphene citrate.","volume":"44","author":"Murakawa","year":"1999","journal-title":"J Reprod Med"},{"key":"2019041121320420100_R291","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1210\/jcem.82.2.3727","article-title":"The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome.","volume":"82","author":"Fulghesu","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R292","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0015-0282(00)00630-0","article-title":"Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage.","volume":"74","author":"Glueck","year":"2000","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R293","first-page":"127","article-title":"Structural studies, localization in tissue and clinical aspects of human endometrial proteins.","volume":"36","author":"Seppala","year":"1988","journal-title":"J Reprod Fertil Suppl"},{"key":"2019041121320420100_R294","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(87)90235-2","article-title":"Identification of placental protein 14 as an immunosuppressive factor in human reproduction.","volume":"1","author":"Bolton","year":"1987","journal-title":"Lancet"},{"key":"2019041121320420100_R295","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0015-0282(16)57303-8","article-title":"Vaginal color Doppler assessment of uterine artery impedance correlates with immunohistochemical markers of endometrial receptivity required for the implantation of an embryo.","volume":"63","author":"Steer","year":"1995","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R296","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor \u03b3 (PPAR \u03b3).","volume":"270","author":"Lehmann","year":"1995","journal-title":"J Biol Chem"},{"key":"2019041121320420100_R297","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/endo.137.1.8536636","article-title":"Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-\u03b1, -\u03b2, and -\u03b3 in the adult rat.","volume":"137","author":"Braissant","year":"1996","journal-title":"Endocrinology"},{"key":"2019041121320420100_R298","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1172\/JCI118703","article-title":"Regulation of PPAR \u03b3 gene expression by nutrition and obesity in rodents.","volume":"97","author":"Vidal-Puig","year":"1996","journal-title":"J Clin Invest"},{"key":"2019041121320420100_R299","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1172\/JCI1235","article-title":"Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.","volume":"101","author":"Okuno","year":"1998","journal-title":"J Clin Invest"},{"key":"2019041121320420100_R300","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2337\/diab.37.11.1549","article-title":"Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob\/ob mice and Zucker fatty rats.","volume":"37","author":"Fujiwara","year":"1988","journal-title":"Diabetes"},{"key":"2019041121320420100_R301","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/0026-0495(95)90010-1","article-title":"Acute effects of troglitazone on in vivo insulin action in normal rats.","volume":"44","author":"Lee","year":"1995","journal-title":"Metabolism"},{"key":"2019041121320420100_R302","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.2337\/diab.45.11.1556","article-title":"Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats.","volume":"45","author":"Fulgencio","year":"1996","journal-title":"Diabetes"},{"key":"2019041121320420100_R303","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/endo.134.1.8275942","article-title":"Altered gene expression for tumor necrosis factor-\u03b1 and its receptors during drug and dietary modulation of insulin resistance.","volume":"134","author":"Hofmann","year":"1994","journal-title":"Endocrinology"},{"key":"2019041121320420100_R304","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0092-8674(00)81359-8","article-title":"Adipogenesis and obesity: rounding out the big picture.","volume":"87","author":"Spiegelman","year":"1996","journal-title":"Cell"},{"key":"2019041121320420100_R305","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0889-8529(05)70267-X","article-title":"Thiazolidinediones.","volume":"26","author":"Henry","year":"1997","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2019041121320420100_R306","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1464-5491.1999.00023.x","article-title":"Thiazolidinediones: a new class of antidiabetic drugs.","volume":"16","author":"Day","year":"1999","journal-title":"Diabet Med"},{"key":"2019041121320420100_R307","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/S0140-6736(00)04960-6","article-title":"Lessons from the glitazones: a story of drug development.","volume":"357","author":"Gale","year":"2001","journal-title":"Lancet"},{"key":"2019041121320420100_R308","first-page":"1626","article-title":"Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.","volume":"86","author":"Azziz","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R309","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0015-0282(98)00454-3","article-title":"Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome.","volume":"71","author":"Hasegawa","year":"1999","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R310","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2337\/diabetes.48.2.254","article-title":"Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-\u03b3.","volume":"48","author":"Wang","year":"1999","journal-title":"Diabetes"},{"key":"2019041121320420100_R311","doi-asserted-by":"crossref","first-page":"16767","DOI":"10.1074\/jbc.M100040200","article-title":"Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3\u03b2-hydroxysteroid dehydrogenase.","volume":"276","author":"Arlt","year":"2001","journal-title":"J Biol Chem"},{"key":"2019041121320420100_R312","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1095\/biolreprod66.1.190","article-title":"Putative activation of the peroxisome proliferator-activated receptor \u03b3 impairs androgen and enhances progesterone biosynthesis in primary cultures of porcine theca cells.","volume":"66","author":"Schoppee","year":"2002","journal-title":"Biol Reprod"},{"key":"2019041121320420100_R313","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1093\/humrep\/14.11.2700","article-title":"High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome.","volume":"14","author":"Mitwally","year":"1999","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R314","doi-asserted-by":"crossref","first-page":"5090","DOI":"10.1210\/jcem.86.10.7963-8","article-title":"Troglitazone use in polycystic ovary syndrome.","volume":"86","author":"Azziz","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R315","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/BF00418542","article-title":"Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.","volume":"39","author":"Kumar","year":"1996","journal-title":"Diabetologia"},{"key":"2019041121320420100_R316","first-page":"3169","article-title":"Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.","volume":"83","author":"Fonseca","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R317","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1463-1326.1999.00020.x","article-title":"Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.","volume":"1","author":"Patel","year":"1999","journal-title":"Diabetes Obes Metab"},{"key":"2019041121320420100_R318","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2337\/diabetes.51.3.797","article-title":"The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.","volume":"51","author":"Mayerson","year":"2002","journal-title":"Diabetes"},{"key":"2019041121320420100_R319","doi-asserted-by":"crossref","first-page":"708","DOI":"10.2337\/diacare.25.4.708","article-title":"A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.","volume":"25","author":"Khan","year":"2002","journal-title":"Diabetes Care"},{"key":"2019041121320420100_R320","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/jcem.87.6.8567","article-title":"Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.","volume":"87","author":"Miyazaki","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R321","first-page":"1","volume":"rsqb","author":"Randle","year":"1994","journal-title":"J Cell Biol 55[suppl"},{"key":"2019041121320420100_R322","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/(SICI)1099-0895(199603)12:1<15::AID-DMR155>3.0.CO;2-0","article-title":"Interactions between glucose and FFA metabolism in man.","volume":"12","author":"Saloranta","year":"1996","journal-title":"Diabetes Metab Rev"},{"key":"2019041121320420100_R323","doi-asserted-by":"crossref","first-page":"308","DOI":"10.2337\/diacare.24.2.308","article-title":"Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.","volume":"24","author":"Phillips","year":"2001","journal-title":"Diabetes Care"},{"key":"2019041121320420100_R324","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1210\/jcem.86.1.7157","article-title":"Rosiglitazone monotherapy is effective in patients with type 2 diabetes.","volume":"86","author":"Lebovitz","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R325","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s001250050045","article-title":"Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.","volume":"43","author":"Raskin","year":"2000","journal-title":"Diabetologia"},{"key":"2019041121320420100_R326","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/diacare.23.11.1605","article-title":"Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone Study Group.","volume":"23","author":"Aronoff","year":"2000","journal-title":"Diabetes Care"},{"key":"2019041121320420100_R327","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2165\/00003495-200060020-00009","article-title":"Pioglitazone.","volume":"60","author":"Gillies","year":"2000","journal-title":"Drugs"},{"key":"2019041121320420100_R328","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0015-0282(01)02843-6","article-title":"Improvement in insulin sensitivity followed by ovulation and pregnancy in a women with polycystic ovary syndrome who was treated with rosiglitazone.","volume":"76","author":"Cataldo","year":"2001","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R329","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2337\/diabetes.47.4.507","article-title":"PPAR-\u03b3: adipogenic regulator and thiazolidinedione receptor.","volume":"47","author":"Spiegelman","year":"1998","journal-title":"Diabetes"},{"key":"2019041121320420100_R330","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1152\/ajplegacy.1975.229.1.49","article-title":"Use of diphenylhydantoin and diazoxide to investigate insulin secretory mechanism.","volume":"229","author":"Levin","year":"1975","journal-title":"Am J Physiol"},{"key":"2019041121320420100_R331","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/0002-9378(90)90698-7","article-title":"Suppression of serum insulin level by diazoxide does not alter serum testosterone or sex hormone-binding globulin levels in healthy, nonobese women.","volume":"163","author":"Nestler","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"2019041121320420100_R332","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.2501869","article-title":"Hyperpolarizing vasodilators activate ATP-sensitive K channels in arterial smooth muscle.","volume":"245","author":"Standen","year":"1989","journal-title":"Science"},{"key":"2019041121320420100_R333","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1172\/JCI106628","article-title":"Diazoxide effects on biphasic insulin release: adrenergic suppression and enhancement in the perifused rat pancreas.","volume":"50","author":"Burr","year":"1971","journal-title":"J Clin Invest"},{"key":"2019041121320420100_R334","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1530\/eje.0.1390184","article-title":"Leptin levels in women with polycystic ovary syndrome before a treatment with diazoxide.","volume":"139","author":"Krassas","year":"1998","journal-title":"Eur J Endocrinol"},{"key":"2019041121320420100_R335","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/00000441-196309000-00009","article-title":"Diazoxide therapy in hypertension.","volume":"246","author":"Lockwood","year":"1963","journal-title":"Am J Med Sci"},{"key":"2019041121320420100_R336","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2165\/00003495-198835030-00003","article-title":"Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.","volume":"35","author":"Clissold","year":"1988","journal-title":"Drugs"},{"key":"2019041121320420100_R337","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2165\/00003088-199630020-00002","article-title":"Pharmacokinetic-pharmacodynamic relationships of acarbose.","volume":"30","author":"Salvatore","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"2019041121320420100_R338","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2337\/diacare.12.8.537","article-title":"Effects of 8-wk \u03b1-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.","volume":"12","author":"Schnack","year":"1989","journal-title":"Diabetes Care"},{"key":"2019041121320420100_R339","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2337\/diacare.13.3.32","article-title":"Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sufonylureas.","volume":"13","author":"Reaven","year":"1993","journal-title":"Diabetes Care"},{"key":"2019041121320420100_R340","first-page":"559","article-title":"Low-dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity.","volume":"16","author":"Jenney","year":"1996","journal-title":"Diabetes Care"},{"key":"2019041121320420100_R341","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/diacare.19.11.1190","article-title":"The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.","volume":"19","author":"Chiasson","year":"1996","journal-title":"Diabetes Care"},{"key":"2019041121320420100_R342","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0026-0495(96)90139-0","article-title":"Improvement of insulin sensitivity and dyslipidemia with a new \u03b1-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects.","volume":"45","author":"Shinozaki","year":"1996","journal-title":"Metabolism"},{"key":"2019041121320420100_R343","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2337\/diacare.19.6.559","article-title":"Does suppression of postprandial blood glucose excursions by the \u03b1-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?","volume":"19","author":"Johnson","year":"1996","journal-title":"Diabetes Care"},{"key":"2019041121320420100_R344","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1055\/s-0029-1211981","article-title":"The effects of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance.","volume":"106","author":"Laube","year":"1998","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2019041121320420100_R345","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/diacare.21.2.256","article-title":"Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients.","volume":"21","author":"Matsumoto","year":"1998","journal-title":"Diabetes Care"},{"key":"2019041121320420100_R346","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/oxfordjournals.humrep.a019118","article-title":"Acarbose reduces elevated testosterone serum concentrations in hyperinsulinaemic premenopausal women: a pilot study.","volume":"11","author":"Geisthovel","year":"1996","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R347","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1210\/endo.130.5.1349280","article-title":"Photoaffinity labeling of the somatostatin receptor. Identification of molecular subtypes.","volume":"130","author":"Srikant","year":"1992","journal-title":"Endocrinology"},{"key":"2019041121320420100_R348","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0024-3205(82)90087-X","article-title":"SMS 201\u2013995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.","volume":"31","author":"Bauer","year":"1982","journal-title":"Life Sci"},{"key":"2019041121320420100_R349","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0026-0495(92)90036-A","article-title":"Effects of the somatostatin analogue, octreotide, in polycystic ovary syndrome.","volume":"41","author":"Prelevic","year":"1992","journal-title":"Metabolism"},{"key":"2019041121320420100_R350","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1093\/humrep\/14.12.2951","article-title":"Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinemia or lean normoinsulinaemia.","volume":"14","author":"Ciotta","year":"1999","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R351","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S0015-0282(16)57475-5","article-title":"Alterations in the sensitivity of serum insulin-like growth factor 1 and insulin-like growth factor binding protein-3 to octreotide in polycystic ovary syndrome.","volume":"63","author":"Morris","year":"1995","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R352","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/humrep\/10.1.28","article-title":"The effects of the somatostatin analogue octreotide on ovulatory performance in women with polycystic ovaries.","volume":"10","author":"Prelevic","year":"1995","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R353","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0015-0282(98)00475-0","article-title":"Octreotide is not useful for clomiphene citrate resistance in patients with polycystic ovary syndrome but may reduce the likelihood of ovarian hyperstimulation syndrome.","volume":"71","author":"Morris R","year":"1999","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R354","first-page":"167","article-title":"Multiple pathways in insulin signalling: fitting the covalent and allosteric puzzle pieces together.","volume":"2","author":"Larner","year":"1994","journal-title":"Endocr J"},{"key":"2019041121320420100_R355","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1210\/endo.132.2.8425483","article-title":"Chiroinositol deficiency and insulin resistance. Urinary excretion rate of chiroinositol is directly associated with insulin resistance in spontaneously diabetic rhesus monkeys.","volume":"132","author":"Ortmeyer","year":"1993","journal-title":"Endocrinology"},{"key":"2019041121320420100_R356","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.2337\/diacare.17.12.1465","article-title":"Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type II diabetes.","volume":"17","author":"Suzuki","year":"1994","journal-title":"Diabetes Care"},{"key":"2019041121320420100_R357","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJM199008093230603","article-title":"Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus.","volume":"323","author":"Kennington","year":"1990","journal-title":"N Engl J Med"},{"key":"2019041121320420100_R358","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1073\/pnas.90.13.5924","article-title":"Chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects.","volume":"90","author":"Asplin","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019041121320420100_R359","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJM199904293401703","article-title":"Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome.","volume":"340","author":"Nestler","year":"1999","journal-title":"N Engl J Med"},{"key":"2019041121320420100_R360","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1210\/jcem-68-1-173","article-title":"Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss.","volume":"68","author":"Pasquali","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R361","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2265.1992.tb02909.x","article-title":"Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome.","volume":"36","author":"Kiddy","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041121320420100_R362","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0015-0282(16)48154-9","article-title":"Weight loss is associated with correction of gonadotropin and sex steroid abnormalities in the obese anovulatory female.","volume":"42","author":"Harlass","year":"1984","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R363","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0015-0282(16)56632-1","article-title":"Endocrine consequences of weight loss in obese, hyperandrogenic anovulatory women.","volume":"61","author":"Guzick","year":"1994","journal-title":"Fertil Steril"},{"key":"2019041121320420100_R364","first-page":"2586","article-title":"Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome.","volume":"80","author":"Holte","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R365","first-page":"1470","article-title":"Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome.","volume":"84","author":"Huber-Bucholz","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R366","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/humrep\/12.suppl_1.82","article-title":"Weight control and its beneficial effect on fertility in women with obesity and polycystic ovary syndrome.","volume":"12","author":"Pasquali","year":"1997","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R367","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJM199108153250703","article-title":"The effects on plasma lipoproteins of a prudent weight-reducing diet with or without exercise, in overweight men and women.","volume":"325","author":"Wood","year":"1991","journal-title":"N Engl J Med"},{"key":"2019041121320420100_R368","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/0026-0495(95)90118-3","article-title":"Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome.","volume":"44","author":"Andersen","year":"1995","journal-title":"Metabolism"},{"key":"2019041121320420100_R369","first-page":"64","article-title":"Insulin resistance, secretion, and metabolism in users of oral contraceptives.","volume":"74","author":"Godsland","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R370","first-page":"3327","article-title":"Metabolic effects of oral contraceptives in women with polycystic ovary syndrome.","volume":"80","author":"Korytkowski","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121320420100_R371","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/humrep\/17.7.1729","article-title":"Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study.","volume":"17","author":"Elter","year":"2002","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R372","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"2019041121320420100_R373","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"2019041121320420100_R374","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1071-55760200260-5","article-title":"Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy.","volume":"10","author":"Shobokshi","year":"2003","journal-title":"J Soc Gynecol Investig"},{"key":"2019041121320420100_R375","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/humrep\/deg264","article-title":"Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.","volume":"18","author":"Romualdi","year":"2003","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R376","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/humrep\/deg343","article-title":"Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin.","volume":"18","author":"Glueck","year":"2003","journal-title":"Hum Reprod"},{"key":"2019041121320420100_R377","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0015-0282(02)04843-4","article-title":"Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome.","volume":"79","author":"Ghazeeri","year":"2003","journal-title":"Fertil Steril"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/edrv\/article-pdf\/24\/5\/633\/8861278\/edrv0633.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T03:33:21Z","timestamp":1704944001000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/24\/5\/633\/2424413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10,1]]},"references-count":377,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,11,7]]},"published-print":{"date-parts":[[2003,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/er.2002-0015","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10,1]]}}}